These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22787118)

  • 1. A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.
    Le Poul E; Boléa C; Girard F; Poli S; Charvin D; Campo B; Bortoli J; Bessif A; Luo B; Koser AJ; Hodge LM; Smith KM; DiLella AG; Liverton N; Hess F; Browne SE; Reynolds IJ
    J Pharmacol Exp Ther; 2012 Oct; 343(1):167-77. PubMed ID: 22787118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
    Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.
    Kalinichev M; Le Poul E; Boléa C; Girard F; Campo B; Fonsi M; Royer-Urios I; Browne SE; Uslaner JM; Davis MJ; Raber J; Duvoisin R; Bate ST; Reynolds IJ; Poli S; Celanire S
    J Pharmacol Exp Ther; 2014 Sep; 350(3):495-505. PubMed ID: 24947466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
    Jones CK; Bubser M; Thompson AD; Dickerson JW; Turle-Lorenzo N; Amalric M; Blobaum AL; Bridges TM; Morrison RD; Jadhav S; Engers DW; Italiano K; Bode J; Daniels JS; Lindsley CW; Hopkins CR; Conn PJ; Niswender CM
    J Pharmacol Exp Ther; 2012 Feb; 340(2):404-21. PubMed ID: 22088953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Putative mGluR4 positive allosteric modulators activate G
    Abulwerdi G; Stoica BA; Loane DJ; Faden AI
    Neurochem Int; 2020 Sep; 138():104770. PubMed ID: 32454165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.
    Niswender CM; Johnson KA; Weaver CD; Jones CK; Xiang Z; Luo Q; Rodriguez AL; Marlo JE; de Paulis T; Thompson AD; Days EL; Nalywajko T; Austin CA; Williams MB; Ayala JE; Williams R; Lindsley CW; Conn PJ
    Mol Pharmacol; 2008 Nov; 74(5):1345-58. PubMed ID: 18664603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia.
    Finlay CJ; Jackson MJ; Fisher R; Bundgaard C; Rose S; Duty S
    J Parkinsons Dis; 2024; 14(2):245-259. PubMed ID: 38427500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease.
    Lindsley CW; Niswender CM; Engers DW; Hopkins CR
    Curr Top Med Chem; 2009; 9(10):949-63. PubMed ID: 19754407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
    Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ
    ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiosynthesis and evaluation of 5-methyl-N-(4-[(11)C]methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine ([(11)C]ADX88178) as a novel radioligand for imaging of metabotropic glutamate receptor subtype 4 (mGluR4).
    Fujinaga M; Yamasaki T; Nengaki N; Ogawa M; Kumata K; Shimoda Y; Yui J; Xie L; Zhang Y; Kawamura K; Zhang MR
    Bioorg Med Chem Lett; 2016 Jan; 26(2):370-374. PubMed ID: 26707390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of metabotropic glutamate receptor 4-positive allosteric modulator TAS-4 in rodent models of movement disorders.
    Dube A; Chaudhary S; Mengawade T; Upasani CD
    J Neurol Sci; 2014 Jul; ():. PubMed ID: 25073574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
    Johnson KA; Jones CK; Tantawy MN; Bubser M; Marvanova M; Ansari MS; Baldwin RM; Conn PJ; Niswender CM
    Neuropharmacology; 2013 Mar; 66():187-95. PubMed ID: 22546615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
    Célanire S; Campo B
    Expert Opin Drug Discov; 2012 Mar; 7(3):261-80. PubMed ID: 22468956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression of excitatory transmission at PF-PC synapse by group III metabotropic glutamate receptors is provided exclusively by mGluR4 in the rodent cerebellar cortex.
    Abitbol K; Acher F; Daniel H
    J Neurochem; 2008 Jun; 105(6):2069-79. PubMed ID: 18266929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.
    Marino MJ; Williams DL; O'Brien JA; Valenti O; McDonald TP; Clements MK; Wang R; DiLella AG; Hess JF; Kinney GG; Conn PJ
    Proc Natl Acad Sci U S A; 2003 Nov; 100(23):13668-73. PubMed ID: 14593202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors.
    Marino MJ; Conn PJ
    Curr Opin Pharmacol; 2006 Feb; 6(1):98-102. PubMed ID: 16368268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model.
    Vernon AC; Croucher MJ; Dexter DT
    Neuroreport; 2008 Mar; 19(4):475-8. PubMed ID: 18287950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
    Gilmour G; Broad LM; Wafford KA; Britton T; Colvin EM; Fivush A; Gastambide F; Getman B; Heinz BA; McCarthy AP; Prieto L; Shanks E; Smith JW; Taboada L; Edgar DM; Tricklebank MD
    Neuropharmacology; 2013 Jan; 64():224-39. PubMed ID: 22884720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
    Austin PJ; Betts MJ; Broadstock M; O'Neill MJ; Mitchell SN; Duty S
    Br J Pharmacol; 2010 Aug; 160(7):1741-53. PubMed ID: 20649576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.